Abstract:We conducted this meta-analysis of relevant case–control studies to investigate the relationships between genetic polymorphisms in VDR, ESR1 and ESR2 genes to the susceptibility of Parkinson’s disease (PD). A search on electronic databases without any language restrictions was conducted: MEDLINE (1966–2013), the Cochrane Library Database (Issue 12, 2013), EMBASE (1980–2013), CINAHL (1982–2013), Web of Science (1945–2013) and the Chinese Biomedical Database (1982–2013). Meta-analysis was performed using the STATA statistical software. Crude odds ratio (OR) with their 95 % confidence interval (95 % CI) was calculated. Fourteen case–control studies with a total of 3,689 PD patients and 4,627 healthy subjects were included in our meta-analysis. The results of our meta-analysis demonstrated that the VDR genetic polymorphisms might be closely related to increased risks of PD (allele model: OR = 1.18, 95 % CI 1.09–1.29, P < 0.001; dominant model: OR = 1.37, 95 % CI 1.16–1.63, P < 0.001; respectively), especially for the polymorphisms rs7976091 and rs10735810. Our findings also illustrated that ESR1 genetic polymorphisms might increase the risk of PD (allele model: OR = 1.56, 95 % CI 1.17–2.07, P = 0.002; recessive model: OR = 1.93, 95 % CI 1.33–2.80, P < 0.001; homozygous model: OR = 1.35, 95 % CI 1.02–1.79, P = 0.038; heterozygous model: OR = 2.04, 95 % CI 1.36–3.07, P = 0.001; respectively), especially for the polymorphisms rs2234693 and rs9340799. Furthermore, we found significant correlations of ESR2 genetic polymorphisms with the risk of PD (allele model: OR = 1.78, 95 % CI 1.19–2.67, P = 0.005; recessive model: OR = 1.93, 95 % CI 1.15–3.27, P = 0.014; homozygous model: OR = 1.77, 95 % CI 1.09–2.89, P = 0.022; heterozygous model: OR = 1.88, 95 % CI 1.08–3.27, P = 0.025; respectively), especially for the rs1256049 polymorphism. Our meta-analysis suggests that genetic polymorphisms in VDR, ESR1 and ESR2 genes may contribute to increased risks for PD.

Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African‐Caribbean inpatients: Differences in association with dopamine and serotonin receptors

Association of the DRD2 CAn-STR and DRD3 Ser9Gly Polymorphisms with Parkinson's Disease and Response to Dopamine Agonists.

An Association Study of the Cytochromes P4502D6, the Dopamine D2 Receptor Gene Polymorphisms and Efficacy of Risperidone

Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis.

The Relationship Between the Therapeutic Response to Risperidone and the Dopamine D(2) Receptor Polymorphism in Chinese Schizophrenia Patients

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease

Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D617 and CYP2D629, When Compared with Normal Metabolizers

Pharmacogenetics of Treatment in First-Episode Schizophrenia: D3 and 5-HT2C Receptor Polymorphisms Separately Associate with Positive and Negative Symptom Response

A Pharmacogenomic Study on the Polymorphic Gene Response to Risperidone in Schizophrenia Patients.

Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson’s disease patients

DRD3 Ser9Gly polymorphism and treatment response to antipsychotics in schizophrenia: A meta-analysis

Effects of the Dopamine D3 Receptor (DRD3) Gene Polymorphisms on Risperidone Response: a Pharmacogenetic Study.

Pharacogenetic Effects of Dopamine Transporter Gene Polymorphisms on Response to Chlorpromazine and Clozapine and on Extrapyramidal Syndrome in Schizophrenia

BDNF rs10501087, rs1491850 and rs11030094 polymorphisms associated with delayed progression in early-stage Parkinson's disease

Dopamine Transporter Polymorphisms and Risperidone Response in Chinese Schizophrenia Patients: an Association Study.

Association Study Between DRD2, DRD3 Genetic Polymorphisms and Adverse Reactions in Chinese Patients on Amisulpride Treatment

The --1019 C/G Polymorphism of the 5-HT(1)A Receptor Gene is Associated with Negative Symptom Response to Risperidone Treatment in Schizophrenia Patients.

DRD3 Predicts Cognitive Impairment and Anxiety in Parkinson's Disease: Susceptibility and Protective Effects

RETRACTED ARTICLE: Genetic Polymorphisms in VDR, ESR1 and ESR2 Genes May Contribute to Susceptibility to Parkinson’s Disease: a Meta-Analysis

Dopamine Beta Hydroxylase Gene Polymorphism and Parkinson's Disease

Response To Chlorpromazine Treatment May Be Associated With Polymorphisms Of The Drd2 Gene In Chinese Schizophrenic Patients